Increase saliva production

"Increase saliva production" refers to the enhancement of the amount of saliva secreted by the salivary glands, primarily achieved through stimulation of muscarinic acetylcholine receptors (notably M3 subtype) on salivary acinar cells, either via endogenous parasympathetic cholinergic signaling or by pharmacological agents known as sialogogues. This is a therapeutic goal in conditions such as xerostomia (dry mouth) and Sjögren syndrome[1][3][4][5][7]. Direct molecular targets involved in this process include muscarinic acetylcholine receptors and, to a lesser extent, adrenergic receptors and neuropeptide receptors (e.g., neurokinin-1). Drugs increasing saliva production typically act as cholinergic agonists or acetylcholinesterase inhibitors, thereby enhancing acetylcholine-mediated signaling to salivary glands. Note: For structured molecular or receptor target information, see individual entities such as "Muscarinic acetylcholine receptor M3", "Neurokinin-1 receptor", or "Beta-1 adrenergic receptor" rather than the non-molecular entry "Increase saliva production"[1][3][4][7].

Other names

Increase salivary flowStimulate saliva secretionSalivation enhancement

Muscarinic acetylcholine receptor agonism (especially M3, leading to increased acinar cell secretion)[1][3][4][7] Stimulation of parasympathetic nervous system to release acetylcholine Indirectly, by blocking acetylcholinesterase (increasing acetylcholine availability)